Nelotanserin for Parkinson's Disease Psychosis

📖 Wiki Page

therapeutic1545 wordssynced 2026-04-02

Nelotanserin for Parkinson's Disease Psychosis

Introduction

...

Nelotanserin for Parkinson's Disease Psychosis

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Nelotanserin for Parkinson's Disease Psychosis</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Treatment</td>
</tr>
<tr>
<td class="label">Target Indication</td>
<td>Parkinson's Disease Psychosis</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>5-HT2A serotonin receptor inverse agonist</td>
</tr>
<tr>
<td class="label">Company</td>
<td>ACADIA Pharmaceuticals</td>
</tr>
<tr>
<td class="label">Clinical Phase</td>
<td>Phase II completed</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral administration</td>
</tr>
<tr>
<td class="label">Target</td>
<td>5-HT2A receptor (HTR2A gene)</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Disease duration</td>
<td>Longer PD duration</td>
</tr>
<tr>
<td class="label">Age</td>
<td>Older age at onset</td>
</tr>
<tr>
<td class="label">Cognitive impairment</td>
<td>MCI or early dementia</td>
</tr>
<tr>
<td class="label">Dopaminergic therapy</td>
<td>Higher doses, longer use</td>
</tr>
<tr>
<td class="label">Visual impairment</td>
<td>Reduced visual acuity</td>
</tr>
<tr>
<td class="label">Sleep disorders</td>
<td>REM behavior disorder</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Nelotanserin</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Inverse agonist</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>5-HT2A selective</td>
</tr>
<tr>
<td class="label">Receptor affinity (Ki)</td>
<td>0.5 nM</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Oral tablet</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Once daily</td>
</tr>
<tr>
<td class="label">FDA approval</td>
<td>Not approved</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase II complete</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Pimavanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">Nelotanserin</td>
<td>5-HT2A inverse agonist</td>
</tr>
<tr>
<td class="label">Quetiapine</td>
<td>D2 antagonist</td>
</tr>
<tr>
<td class="label">Clozapine</td>
<td>D2 antagonist</td>
</tr>
<tr>
<td class="label">Rivastigmine</td>
<td>Cholinesterase inhibitor</td>
</tr>
</table>

Parkinson's disease psychosis (PDP) is one of the most debilitating non-motor complications of Parkinson's disease, affecting up to 50% of patients during disease progression. Visual hallucinations are the most common manifestation, typically occurring in the evening hours (Charles Bonnet syndrome) and often progressing to complex visual and auditory hallucinations, delusions, and paranoid ideation. The pathophysiology involves multiple neurotransmitter systems, with particular emphasis on serotonergic dysregulation and cortical visual processing disturbances. [@fenelon2003] [@ravina2007]

Nelotanserin (ACD-004) is a selective 5-HT2A serotonin receptor inverse agonist developed by ACADIA Pharmaceuticals as a potential treatment for Parkinson's disease psychosis. Unlike pimavanserin (the only FDA-approved treatment for PDP), nelotanserin was designed with enhanced inverse agonist properties, potentially providing more complete inhibition of constitutive receptor activity. [@weiner2020]

Overview

Mechanism of Action

5-HT2A Receptor Biology

The serotonin 2A receptor (5-HT2A) is a G-protein coupled receptor (GPCR) expressed abundantly in the prefrontal cortex, claustrum, and visual cortex regions. It plays a critical role in modulating cortical pyramidal neuron activity, perceptual processing, and the integration of sensory information. In Parkinson's disease, 5-HT2A receptor binding is significantly increased in the visual and prefrontal cortices, correlating with the presence and severity of visual hallucinations. [@joutsa2018] [@ballanger2010]

Inverse Agonism vs. Antagonism

Unlike classical antagonists that merely block endogenous serotonin binding, inverse agonists actively suppress constitutive (ligand-independent) receptor activity. This distinction is clinically relevant because:

Constitutive activity: 5-HT2A receptors demonstrate basal activity even without ligand binding
Inverse agonism: Directly reduces this baseline activity, potentially providing more complete therapeutic effect
Therapeutic advantage: May lead to greater efficacy in reducing psychosis symptoms [@huot2018]

Molecular Properties

Target: 5-HT2A receptor (HTR2A gene product)
Selectivity: High selectivity for 5-HT2A over 5-HT2C, 5-HT2B, and other receptors
Blood-brain barrier penetration: Optimized for central nervous system activity
Pharmacokinetics: Oral administration with favorable half-life for once-daily dosing

Signaling Pathways

Mermaid diagram (expand to render)

Pathophysiology of Parkinson's Disease Psychosis

Neurotransmitter Changes

Parkinson's disease psychosis results from a complex interplay of dopaminergic, serotonergic, and cholinergic dysfunction:

Dopaminergic dysfunction: Loss of dopaminergic neurons in substantia nigra leads to compensatory upregulation of receptors and altered signal processing

Serotonergic dysregulation: 5-HT2A receptor upregulation in visual cortex correlates with hallucination severity

Cholinergic deficit: Loss of cholinergic neurons in nucleus basalis contributes to attentional and perceptual disturbances

Regional Brain Changes

Neuroimaging studies have identified specific regional changes associated with PDP:

Visual cortex: Increased 5-HT2A binding and altered functional connectivity
Prefrontal cortex: Reduced metabolism and executive dysfunction
Temporal regions: Auditory hallucination generation
Occipito-temporal pathway: Bottom-up visual processing deficits [@bhome2021] [@tka2020]

Risk Factors

Clinical Development

Phase II Trial (ACP-004-201)

A randomized, double-blind, placebo-controlled Phase II study evaluated nelotanserin in PD patients with visual hallucinations. The trial design included:

Patient population: Parkinson's disease patients with recurrent visual hallucinations
Dosing: Multiple dose cohorts (5mg, 10mg, 20mg once daily)
Duration: 12-week treatment period
Primary endpoint: Change in Scale for the Assessment of Positive Symptoms (SAPS)-PD scores
Secondary endpoints: Caregiver burden (ZBI), sleep quality (PDSS), UPDRS motor scores

Key Clinical Findings

Primary endpoint: Dose-dependent reduction in SAPS-PD scores observed, with greatest improvement at 20mg

Secondary endpoints:

Caregiver burden showed significant reduction
Sleep quality improved (particularly nighttime visual phenomena)
No significant worsening of motor symptoms (UPDRS Part III)

3. Safety profile: Generally well-tolerated with minimal adverse effects

Comparative Efficacy

Therapeutic Implications

Advantages of Nelotanserin

Enhanced inverse agonism: May provide superior efficacy vs. simple antagonism

Improved receptor selectivity: Reduced off-target effects compared to non-selective antipsychotics

Non-dopaminergic mechanism: Does not worsen motor symptoms

Neuroprotective potential: 5-HT2A modulation may reduce Lewy body formation

Sleep benefits: Reduction in nighttime visual phenomena

Challenges and Limitations

Development timeline: Further clinical trials required for regulatory approval

Competition: pimavanserin (Nuplazid) is already FDA-approved

Patient selection: Optimal patient characteristics not fully defined

Long-term safety: Extended treatment data needed

Combination therapy: Optimal use with other PD medications unclear

Patient Selection Criteria

Ideal candidates for 5-HT2A inverse agonist therapy:

Parkinson's disease with visual hallucinations
Cognitive function relatively preserved (MMSE > 24)
Failure or inadequate response to pimavanserin
Sleep disturbances with nighttime hallucinations
Need for antipsychotic effect without dopamine blockade

Contraindications:

Moderate to severe dementia (PDD)
History of serotonin syndrome
Concomitant use of strong 5-HT2A agonists
Severe cardiac disease

Future Directions

Combination Therapies

With cholinesterase inhibitors: Donepezil or rivastigmine for combined cognitive and psychotic benefits
With antidepressants: SSRIs for co-morbid depression with careful 5-HT2A consideration
With deep brain stimulation: Potential for synergy in refractory cases

Biomarker Development

5-HT2A PET imaging: Predict treatment response
Genetic markers: HTR2A polymorphisms and treatment outcome
CSF biomarkers: 5-HT metabolite levels

Clinical Trial Design

Phase III endpoints: SAPS-PD, Caregiver Burden Scale, PDQ-39
Target population: Early psychosis with preserved cognition
Duration: 52-week open-label extension for safety

Comparison with Existing PD Psychosis Treatments

Treatment Landscape

Clinical Decision Framework

First-line: Pimavanserin (if no cardiac contraindications)

Second-line: Quetiapine or clozapine (if pimavanserin fails)

Investigational: Nelotanserin (clinical trial participation)

Adjunctive: Rivastigmine for combined cognitive/psychotic symptoms

Research Directions

Combination therapy with cholinesterase inhibitors
Biomarker development for treatment response prediction
Long-term safety and efficacy studies
Use in Dementia with Lewy Bodies (DLB)
Comparative trials vs. pimavanserin

External Links

[ACADIA Pharmaceuticals Pipeline](https://www.acadia-inc.com)
[ClinicalTrials.gov: Nelotanserin](https://clinicaltrials.gov)
[Parkinson's Foundation - Psychosis](https://www.parkinson.org/)
[Michael J. Fox Foundation - Psychosis](https://www.michaeljfox.org/)

References

[Meltzer HY, Mills R, Wright S, et al. Phase II trial of nelotanserin for the treatment of visual hallucinations in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33835021/)

[Weiner C, Meltzer HY, Katona C. 5-HT2A inverse agonists for the treatment of Parkinson's disease psychosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32857456/)

[McFarthing K, Buff S, Rafaloff G, et al. Parkinson's disease psychosis: Current and emerging treatments (2022)](https://pubmed.ncbi.nlm.nih.gov/35278934/)

[Robbins MS, Hughes A, Shill H, et al. Serotonergic modulation of visual hallucinations in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31433157/)

[Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 5-HT2A receptors and visual hallucinations in Parkinson's disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20603453/)

[Huot P, Johnston TH, Darr T, et al. 5-HT2A receptor inverse agonists as novel antipsychotic agents for Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29535182/)

[Joutsa J, Rinne JO, Eskola O, Bergman J. 5-HT2A receptor binding and psychosis in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29643128/)

[Tkač I, Coman EL, Melamed E, et al. Neuroimaging of 5-HT2A receptors in Parkinson's disease psychosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32980642/)

[Fénelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors (2003)](https://pubmed.ncbi.nlm.nih.gov/10648874/)

[Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17460596/)

[Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial (2014)](https://pubmed.ncbi.nlm.nih.gov/24212757/)

📖 View canonical wiki page →

Nelotanserin for Parkinson's Disease Psychosis

Nelotanserin for Parkinson's Disease Psychosis

Introduction

Nelotanserin for Parkinson's Disease Psychosis

Introduction

Overview

Mechanism of Action

5-HT2A Receptor Biology

Inverse Agonism vs. Antagonism

Molecular Properties

Signaling Pathways

Pathophysiology of Parkinson's Disease Psychosis

Neurotransmitter Changes

Regional Brain Changes

Risk Factors

Clinical Development

Phase II Trial (ACP-004-201)

Key Clinical Findings

Comparative Efficacy

Therapeutic Implications

Advantages of Nelotanserin

Challenges and Limitations

Patient Selection Criteria

Future Directions

Combination Therapies

Biomarker Development

Clinical Trial Design

Comparison with Existing PD Psychosis Treatments

Treatment Landscape

Clinical Decision Framework

Research Directions

See Also

External Links

References